Alosetron (lotronex) revisited.
D002243:Carbolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003109:Colonic Diseases, Functional / Q000188:drug therapy; D003248:Constipation / Q000139:chemically induced; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D011358:Product Surveillance, Postmarketing / Q000592:standards
D002243:Carbolines; C090840:alosetron